PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT02756130: Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Official title: A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)
Conditions: High Grade Fallopian Tube Serous Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Summary: This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions:
description: Given IV
name: Birinapant
other_name: TL32711
type: Drug
description: Given IV
name: Carboplatin
other_name: Blastocarb
CBDCA
Carboplat
Carboplatin Hexal
Carboplatino
Carbosin
Carbosol
Carbotec
Displata
Ercar
JM-8
Nealorin
Novoplatinum
Paraplatin
Paraplatin AQ
Paraplatine
Platinwas
Ribocarbo
type: Drug
description: Correlative studies
name: Laboratory Biomarker Analysis
type: Other
description: Correlative studies
name: Pharmacological Study
type: Other
Study arms:
design_group_description: Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
design_group_title: Treatment (birinapant, carboplatin)
design_group_type: Experimental
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: TetraLogic Pharmaceuticals Corp.
California Institute for Regenerative Medicine
Drug name mappings:
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
name: Birinapant
lang: EN
Clinical trial NCT03722108: Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Official title: A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Conditions: Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction
Summary: Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
Interventions:
description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
name: Regorafenib and Irinotecan
other_name: CAMPTO
STIVARGA
type: Combination Product
description: Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
name: Irinotecan
other_name: CAMPTO
type: Drug
Study arms:
design_group_description: Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.
design_group_title: Regorafenib and Irinotecan
design_group_type: Experimental
design_group_description: Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity
design_group_title: Irinotecan
design_group_type: Active Comparator
Sponsor: UNICANCER
Collaborators: Bayer AG
Drug name mappings:
name: 瑞戈非尼
lang: CN
name: Regorafenib
lang: EN
name: レゴラフェニブ水和物
lang: JP
name: 盐酸伊立替康
lang: CN
name: Irinotecan Hydrochloride
lang: EN
name: イリノテカン塩酸塩水和物
lang: JP
Clinical trial NCT02572167: A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Official title: A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Conditions: Hodgkin Lymphoma
Summary: The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
Interventions:
description: 1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
name: brentuximab vedotin
other_name: SGN-35, ADCETRIS
type: Drug
description: 3 mg/kg by intravenous (IV) infusion for up to 4 cycles
name: nivolumab
other_name: BMS-936558, OPDIVO
type: Drug
Study arms:
design_group_description: Brentuximab vedotin plus nivolumab
design_group_title: Brentuximab Vedotin + Nivolumab
design_group_type: Experimental
Sponsor: Seagen, Inc.
Collaborators: Bristol Myers Squibb Co.
Drug name mappings:
name: 纳武利尤单抗
lang: CN
name: Nivolumab
lang: EN
name: ニボルマブ（遺伝子組換え）
lang: JP
name: 维布妥昔单抗
lang: CN
name: Brentuximab Vedotin
lang: EN
name: ブレンツキシマブ ベドチン（遺伝子組換え）
lang: JP
Clinical trial NCT07136285: Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Official title: PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory
Conditions: SCLC, Extensive Stage
Summary: Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Interventions:
description: Olvi-Vec will be administered to patient for 3 days during C1
name: Olvi-Vec
type: Drug
description: After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum （Carboplatin or Cisplatin）will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
name: platinum (cisplatin or carboplatin)
type: Drug
description: After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
name: Etoposide
type: Drug
Study arms:
design_group_description: Olvi-Vec will be administered for 3 days in C1, then starting from C2, platinum (platinum (cisplatin or carboplatin)) and episode are administrated each 21 days till patients could not tolerate.
design_group_title: Experimental
design_group_type: Experimental
Sponsor: Newsoara Biopharma (Shanghai) Co., Ltd.
Collaborators: Genelux Corp.
Drug name mappings:
name: 依托泊苷
lang: CN
name: Etoposide
lang: EN
name: エトポシド
lang: JP
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
name: 纳欧莫洛基
lang: CN
name: Olvimulogene nanivacirepvec
lang: EN
Clinical trial NCT05357794: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Official title: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Conditions: Mycosis Fungoides
Summary: To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy [ULD-TSEBT]) in combination with brentuximab vedotin can help to control mycosis fungoides
Interventions:
description: Given by Vein (IV)
name: Brentuximab vedotin
other_name: Adcetris
SGN-35
type: Drug
Study arms:
design_group_description: Participant will receive radiation therapy to the entire skin surface over the course of 2 days. Each dose will take about 60 to 90 minutes and will vary from one patient to another
design_group_title: Brentuximab vedotin
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: Pfizer Inc.
Drug name mappings:
name: 维布妥昔单抗
lang: CN
name: Brentuximab Vedotin
lang: EN
name: ブレンツキシマブ ベドチン（遺伝子組換え）
lang: JP
Clinical trial NCT02489123: Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Official title: Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide
Conditions: Ann Arbor Stage I Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma
Ann Arbor Stage III Mantle Cell Lymphoma
Ann Arbor Stage IV Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
Summary: This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgen made by the body.
Interventions:
description: Given PO
name: Enzalutamide
other_name: ASP9785
MDV3100
Xtandi
type: Drug
description: Correlative studies
name: Laboratory Biomarker Analysis
type: Other
Study arms:
design_group_description: Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
design_group_title: Treatment (enzalutamide)
design_group_type: Experimental
Sponsor: University of Washington
Collaborators: National Cancer Institute
National Comprehensive Cancer Network, Inc.
Drug name mappings:
name: 恩扎卢胺
lang: CN
name: Enzalutamide
lang: EN
name: エンザルタミド
lang: JP
Clinical trial NCT05163106: Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
Official title: Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.
Conditions: Breast Cancer
HER2-negative Breast Cancer
ER-positive Breast Cancer
Locally Advanced Breast Cancer
Luminal A Breast Cancer
Luminal B Breast Cancer
Summary: Patients with locally advanced (stage III) breast cancer (LABC) are characterized by a significantly worse prognosis compared to patients with primarily operable breast cancer. While neoadjuvant chemotherapy has been the first choice in this situation for several decades, recent evidence suggests that some patients may experience an extraordinary effect from neoadjuvant endocrine treatments involving aromatase inhibitors as monotherapy or in modern drug combinations.Selected LABC patients admitted for treatment will be offered combination therapy including letrozole and ribociclib. The overall goal of the project is to improve understanding of tumor responses and resistance in patients suffering from ER-positive/HER-2 negative locally advanced breast cancer, focusing on the role of the immune system including the gut microbiome.
Interventions:
description: Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
name: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet
other_name: Femara; Kisqali
type: Drug
description: Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
name: Goserelin
other_name: Zoladex
type: Drug
Study arms:
design_group_description: Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months. Premenopausal women will also receive treatment with goserelin 3.6 mg s.c. every 4 weeks.
design_group_title: Ribociclib and Letrozole Arm
design_group_type: Experimental
Sponsor: Akershus Universitetssykehus HF
Collaborators: Novartis AG
Vestre Viken Hospital Trust
Drug name mappings:
name: 来曲唑/琥珀酸瑞博西尼
lang: CN
name: Letrozole/Ribociclib Succinate
lang: EN
name: 醋酸戈舍瑞林
lang: CN
name: Goserelin Acetate
lang: EN
name: ゴセレリン酢酸塩
lang: JP
Clinical trial NCT00743145: Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
Official title: Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
Conditions: Marijuana Smoking
Summary: In heavy marijuana smokers, opioid receptor blockade increases the subjective and cardiovascular effects of marijuana. The current study was designed to clarify opioid-cannabinoid interactions by assessing how naltrexone shifts the dose-response function for marijuana-elicited effects in heavy marijuana smokers. For this within-subject, double-blind study, a marijuana smoking procedure was designed to characterize a dose-response relationship for marijuana's subjective and cardiovascular effects under blinded conditions.
Interventions:
description: Marijuana cigarette containing 0% THC
name: Inactive Marijuana (0% THC)
other_name: Cannabis
type: Drug
description: Marijuana cigarette containing 5.5% THC
name: Active Marijuana (5.5% THC)
other_name: Cannabis
type: Drug
description: Marijuana cigarette containing 6.2% THC
name: Active Marijuana (6.2% THC)
other_name: Cannabis
type: Drug
description: Naltrexone (12mg/70kg)
name: Naltrexone
other_name: Revia
type: Drug
description: Naltrexone (0mg)
name: Placebo naltrexone
other_name: PBO
type: Drug
Study arms:
design_group_description: Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
design_group_title: Placebo naltrexone + Inactive marijuana
design_group_type: Placebo Comparator
design_group_description: Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
design_group_title: Placebo naltrexone + Active marijuana (5.5% THC)
design_group_type: Placebo Comparator
design_group_description: Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
design_group_title: Placebo naltrexone + Active marijuana (6.2% THC)
design_group_type: Placebo Comparator
design_group_description: Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
design_group_title: Naltrexone + Active marijuana (5.5% THC)
design_group_type: Experimental
design_group_description: Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
design_group_title: Naltrexone + Active marijuana (6.2% THC)
design_group_type: Experimental
design_group_description: Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
design_group_title: Naltrexone + Inactive marijuana
design_group_type: Placebo Comparator
Sponsor: The New York State Psychiatric Institute
Collaborators: The Research Foundation for Mental Hygiene, Inc.
National Institute on Drug Abuse
Drug name mappings:
name: 纳曲酮
lang: CN
name: Naltrexone
lang: EN
Clinical trial NCT01974765: Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Official title: A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian
Recurrent Epithelial Ovarian
Fallopian Tube
Primary Peritoneal Carcinoma
Summary: This is a Phase II study. The purpose of this study is to find out what effects, good and/or bad enzalutamide has on the patient and the cancer. All patients who enter the study will be closely monitored for side-effects. If multiple patients develop significant side effects from enzalutamide, the study may be stopped early.
Enzalutamide is an androgen-receptor inhibitor, which means that it blocks the activity of the hormone testosterone. In ovarian, fallopian tube, and primary peritoneal cancers that express the androgen receptor, blocking the androgen-receptor may possibly slow or stop tumor growth. Enzalutamide has been studied in women with breast cancer, but this is the first study using enzalutamide for the treatment of patients with ovarian, primary peritoneal, or fallopian tube cancer.
Interventions:
description: All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
name: Enzalutamide
type: Drug
Study arms:
design_group_description: After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.<br/>All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting.
design_group_title: Enzalutamide
design_group_type: Experimental
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: MediVation, Inc.
Drug name mappings:
name: 恩扎卢胺
lang: CN
name: Enzalutamide
lang: EN
name: エンザルタミド
lang: JP
Clinical trial NCT02062658: Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)
Official title: Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP)
Conditions: Obsessive-Compulsive Disorder
Summary: This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensated for your time and travel. Participants must be between the ages of 18-55.
Interventions:
description: 0.5mg/kg IV
name: Ketamine
other_name: Ketamine hydrochloride
type: Drug
description: A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
name: Exposure and Response Prevention
other_name: EX/RP
type: Behavioral
Study arms:
design_group_description: 0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
design_group_title: Ketamine, Exposure & Response Prevention
design_group_type: Experimental
Sponsor: The New York State Psychiatric Institute
Collaborators: National Institute of Mental Health
Drug name mappings:
name: 盐酸氯胺酮
lang: CN
name: Ketamine Hydrochloride
lang: EN
name: ケタミン塩酸塩
lang: JP
Clinical trial NCT00003334: Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Official title: Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Conditions: Endometrial Cancer
Fallopian Tube Cancer
Ovarian Cancer
Sarcoma
Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and paclitaxel in treating patients who have recurrent or refractory endometrial cancer, fallopian tube cancer, or sarcoma of the female reproductive tract.
Interventions:
name: paclitaxel
type: Drug
name: pegylated liposomal doxorubicin hydrochloride
type: Drug
Study arms:
Sponsor: NYU Langone Health
Collaborators: National Cancer Institute
Drug name mappings:
name: 盐酸多柔比星脂质体
lang: CN
name: Doxorubicin Hydrochloride liposomal
lang: EN
name: 紫杉醇
lang: CN
name: Paclitaxel
lang: EN
name: パクリタキセル
lang: JP
Clinical trial NCT00088998: Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Official title: Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer
Conditions: Breast Cancer
Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel and capecitabine together with bevacizumab works in treating patients with metastatic breast cancer.
Interventions:
name: bevacizumab
type: Biological
name: capecitabine
type: Drug
name: docetaxel
type: Drug
Study arms:
design_group_description: Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.<br/>Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
design_group_title: docetaxel + bevacizumab + capecitabine
design_group_type: Experimental
Sponsor: Alliance Foundation Trials LLC
Collaborators: National Cancer Institute
Drug name mappings:
name: 多西他赛
lang: CN
name: Docetaxel
lang: EN
name: ドセタキセル
lang: JP
name: 贝伐珠单抗
lang: CN
name: Bevacizumab
lang: EN
name: ベバシズマブ（遺伝子組換え）
lang: JP
name: 卡培他滨
lang: CN
name: Capecitabine
lang: EN
name: カペシタビン
lang: JP